Trial Profile
Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamide
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin
- Indications Breast cancer; Ductal carcinoma
- Focus Therapeutic Use
- 17 May 2016 New trial record